BACKGROUND AND OBJECTIVES: Circulating monocytes can be divided into functionally distinct subpopulations according to their surface expression of CD14 and CD16. Monocytes with high-level expression of both antigens (CD14(++)CD16(+), Mo2 cells) are associated with cardiovascular morbidity and mortality in hemodialysis patients. These cells express angiotensin converting enzyme (ACE) on their surface. They are involved in the association of chronic inflammation and cardiovascular disease in kidney patients. Cardiovascular morbidity results from atherosclerosis (plaque-forming, vessel occluding disease) and arteriosclerosis (loss of arterial dampening function). It is unknown whether ACE-expressing proinflammatory monocytes are related to atherosclerosis, arteriosclerosis, or both. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: During baseline examination for a prospective study on monocyte ACE expression and mortality, 60 chronic hemodialysis patients of an academic outpatient center were screened for atherosclerosis by carotid artery ultrasound, for arteriosclerosis by pulse pressure measurement, and for ACE expression on Mo2 cells by flow cytometry. RESULTS: ACE expression on Mo2 monocytes was significantly higher in patients with severe compared with those with little or no carotid atherosclerosis. Mo2 ACE correlated with a score to semiquantify atherosclerosis and remained a significant predictor of carotid plaques in multivariate analysis including the other univariately associated variables of age, hemoglobin A1c, and albumin. Mo2 ACE was not related to pulse pressure. CONCLUSIONS: ACE expression on Mo2, although being a known predictor of mortality and cardiovascular disease in end-stage renal disease patients, may act via enhancement of atherosclerosis rather than arteriosclerosis.
BACKGROUND AND OBJECTIVES: Circulating monocytes can be divided into functionally distinct subpopulations according to their surface expression of CD14 and CD16. Monocytes with high-level expression of both antigens (CD14(++)CD16(+), Mo2 cells) are associated with cardiovascular morbidity and mortality in hemodialysis patients. These cells express angiotensin converting enzyme (ACE) on their surface. They are involved in the association of chronic inflammation and cardiovascular disease in kidneypatients. Cardiovascular morbidity results from atherosclerosis (plaque-forming, vessel occluding disease) and arteriosclerosis (loss of arterial dampening function). It is unknown whether ACE-expressing proinflammatory monocytes are related to atherosclerosis, arteriosclerosis, or both. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: During baseline examination for a prospective study on monocyte ACE expression and mortality, 60 chronic hemodialysis patients of an academic outpatient center were screened for atherosclerosis by carotid artery ultrasound, for arteriosclerosis by pulse pressure measurement, and for ACE expression on Mo2 cells by flow cytometry. RESULTS:ACE expression on Mo2 monocytes was significantly higher in patients with severe compared with those with little or no carotid atherosclerosis. Mo2 ACE correlated with a score to semiquantify atherosclerosis and remained a significant predictor of carotid plaques in multivariate analysis including the other univariately associated variables of age, hemoglobin A1c, and albumin. Mo2 ACE was not related to pulse pressure. CONCLUSIONS:ACE expression on Mo2, although being a known predictor of mortality and cardiovascular disease in end-stage renal diseasepatients, may act via enhancement of atherosclerosis rather than arteriosclerosis.
Authors: Angeles Guerrero; Rafael Montes; José Muñoz-Terol; Alberto Gil-Peralta; Javier Toro; Macarena Naranjo; Paloma González-Pérez; Carmen Martín-Herrera; Ana Ruiz-Fernández Journal: Nephrol Dial Transplant Date: 2006-08-29 Impact factor: 5.992
Authors: G H Heine; C Ulrich; E Seibert; S Seiler; J Marell; B Reichart; M Krause; A Schlitt; H Köhler; M Girndt Journal: Kidney Int Date: 2007-12-26 Impact factor: 10.612
Authors: Kyrill S Rogacev; Christof Ulrich; Lutz Blömer; Florian Hornof; Katrin Oster; Maren Ziegelin; Bodo Cremers; Yvonne Grenner; Jürgen Geisel; Axel Schlitt; Hans Köhler; Danilo Fliser; Matthias Girndt; Gunnar H Heine Journal: Eur Heart J Date: 2009-08-17 Impact factor: 29.983
Authors: B Schieffer; E Schieffer; D Hilfiker-Kleiner; A Hilfiker; P T Kovanen; M Kaartinen; J Nussberger; W Harringer; H Drexler Journal: Circulation Date: 2000-03-28 Impact factor: 29.690
Authors: Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad Journal: N Engl J Med Date: 2009-03-30 Impact factor: 91.245
Authors: M Rutkowska-Zapała; M Suski; R Szatanek; M Lenart; K Węglarczyk; R Olszanecki; T Grodzicki; M Strach; J Gąsowski; M Siedlar Journal: Clin Exp Immunol Date: 2015-05-06 Impact factor: 4.330
Authors: Gunnar H Heine; Alberto Ortiz; Ziad A Massy; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Gianfranco Parati; Rosa Sicari; Carmine Zoccali; Danilo Fliser Journal: Nat Rev Nephrol Date: 2012-03-13 Impact factor: 28.314
Authors: Eric Seibert; Kristina Zohles; Christof Ulrich; Alexander Kluttig; Sebastian Nuding; Jan A Kors; Cees A Swenne; Karl Werdan; Roman Fiedler; Matthias Girndt Journal: BMC Cardiovasc Disord Date: 2016-11-03 Impact factor: 2.298